Sony Pixel Power calrec Sony

October 03, 2018

04/10/2018

ReFRAME drug repurposing collection yields hope for treating diseases that kill millions worldwide Calibr scientists build and deploy new ReFRAME drug collection to find potential therapies against HIV, tuberculosis and parasites that causes severe illness in children.

October 03, 2018

LA JOLLA, CA Oct. 3, 2018 Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

Scientists at Calibr, a non-profit drug discovery division of Scripps Research, are now exploring that question using an extensive library they've built of nearly all existing small-molecule drugs shown to be appropriate for direct use in humans.

The Calibr scientists are using this collection, called ReFRAME, to identify existing drugs that show promise for treating major diseases. As a result of this ReFRAME initiative, two FDA-approved drugs are already being tested in clinical trials one as a treatment for tuberculosis and another for the parasite Cryptosporidium spp., a major cause of severe diarrhea within only a few short years of Calibr scientists discovering their utility. This is in contrast to the much longer timelines that often hinder new drug development.

Now, in another early success of the project and demonstration of its power to quickly find much needed novel therapies, the Calibr researchers used ReFRAME to identify two additional compounds that in preliminary testing appeared effective against Cryptosporidium spp. The results of the new Cryptosporidium study were reported this week in Proceedings of the National Academy of Sciences.

ReFRAME takes the concept of accelerating impact on patients through repurposing existing drugs to a new level, offering great potential for finding much-needed therapies more quickly and cost-effectively, says Pete Schultz, PhD, president and CEO of Scripps Research and Calibr, who is one of the lead researchers on the ReFRAME project. The drugs we've assembled in ReFRAME have already been shown safe in humans, making them an incredibly valuable resource for tackling areas of urgent unmet medical need, especially neglected tropical diseases.

To construct ReFRAME, Calibr researchers gathered data on more than 12,000 small-molecule drugs by combining three widely-used commercial drug databases (Clarivate Integrity, GVK Excelra GoStar and Citeline Pharmaprojects), which are typically used by pharmaceutical and biotech companies to assess competition and guide drug research and development. Calibr researchers also mined patent filings for drug candidates that had not yet reached these databases but that might hold potential as therapies for diseases outside their original therapeutic indications. With these data in hand, Calibr launched a massive campaign to obtain physical samples of all of the compounds, including purchase of about 7,000 compounds and de novo chemical synthesis of about 5,000 compounds, a project that involved around 500 chemists over an 18-month period. Sufficient quantities were generated to enable hundreds of laboratory tests over the coming years, both at Calibr, Scripps Research, and partner organizations around the globe.

ReFRAME was developed as a singular new resource for the global health drug discovery community and is the largest and most comprehensive repurposing collection available, says Arnab Chatterjee, PhD, vice president of medicinal chemistry at Calibr and lead researcher on the project. In addition to consolidating compounds from multiple existing collections, we synthesized around 5,000 molecules that are not commercially available from which we identified the two new hits against Cryptosporidium.

Drugs that have been previously tested for safety in humans offer a major advantage over new compounds, as the time and cost of conducting preclinical trials in animals and early trials in humans represents a major hurdle to bringing new drugs to the clinic. Repurposing an existing drug can overcome these barriers, significantly lowering the cost and time required to develop a new way to prevent or treat a disease.

Repurposing drugs, however, is not as simple as it sounds. Prior to ReFRAME, information on existing drugs was spread across multiple databases. Similarly, there was no single, comprehensive source of samples of the actual drug compounds, so collecting thousands of compounds to test against any given disease was a significant logistical challenge. The Calibr team also synthesized close derivatives of many known drugs and included them in the collection, providing an important resource for screening multiple analogues of molecules for therapeutic applications.

By combining three different commercial data sets and significant patent intelligence, we identified many unique compounds that have never been collected in one place, says Jeff Janes, PhD, a principal investigator at Calibr and coauthor on the paper.

The first two drugs identified for potential repurposing using ReFRAME were the leprosy drug clofazimine and the arthritis drug auranofin. Calibr is collaborating with the University of Washington, who is sponsoring a Phase 2A clinical trial in Malawi, and the Bill and Melinda Gates Foundation to study the safety, tolerability, pharmacokinetics and efficacy of clofazimine in the treatment of cryptosporidiosis in HIV positive patients. Auranofin is currently being tested as a possible treatment for tuberculosis in a clinical trial taking place in South Africa.

In their new study, Calibr scientists used the institute's high-throughput screening facility to test all 12,000 compounds against Cryptosporidium, a one-celled parasite that travels to the small intestine and bores into the intestine wall causing severe diarrhea.
LINK: https://www.scripps.edu/news-and-events/press-room/2018/20181003-refra...
See more stories from scripps

More from Scripps

08/05/2024

May 07, 2024

Professor emeritus John (Jack) Johnson elected to the National Academy of Sciences Johnson's multi-disciplinary research has been instrumental in shaping ou...

03/05/2024

May 02, 2024

TIME100 Health list features Scripps Research Executive Vice President Eric Topol New list honors 100 individuals who most influenced global health in 2024. M...

02/05/2024

May 01, 2024

New technique improves T cell-based immunotherapies for solid tumors Scripps Research scientists help T cells more effectively kill solid tumors cells in vitro ...

20/04/2024

April 19, 2024

New copper-catalyzed C-H activation strategy from Scripps Research Two-mode reactions inspired by human detox enzymes offer powerful new tools for drug discover...

12/04/2024

April 11, 2024

Scripps Research chemists devise easier new method for making a common type of building block for drugs Scientists transform simple linear amines into saturated...

06/04/2024

April 05, 2024

A simple, inexpensive way to make carbon atoms bind together A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules,...

04/04/2024

April 03, 2024

Developing a vaccine for the zombie drug xylazine Scripps Research chemical biologists design an early proof-of-concept vaccine that could lead to the first...

30/03/2024

March 29, 2024

How blocking a neural receptor responsible for addiction could reduce alcohol use A Scripps Research team found that a new therapeutic that targets the kappa op...

13/03/2024

March 13, 2024

New computational strategy boosts the ability of drug designers to target proteins inside the membrane Customized-design approach could streamline the design of...

29/02/2024

February 29, 2024

Scripps Research scientists reveal how first cells could have formed on Earth New phospholipid discovery brings researchers closer to understanding how primordi...

29/02/2024

February 28, 2024

How molecular handedness emerged in early biology Scripps Research chemists fill a major gap in origin-of-life theories. February 28, 2024 LA JOLLA, CA Mole...

22/02/2024

February 21, 2024

Snaking toward a universal antivenom Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms. February 21, 2024 ...

06/02/2024

February 06, 2024

Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases AbbVie...

26/01/2024

January 25, 2024

Re-energizing mitochondria to treat Alzheimer's disease Scripps Research team restored neuron-to-neuron connections in human cells. January 25, 2024 LA JO...

24/01/2024

January 04, 2024

100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health For the last century, institute leaders and renowned scie...

23/01/2024

January 23, 2024

New technology lets researchers track brain cells' off switches The method could shed light on what goes awry in numerous brain conditions when neurons ar...

09/01/2024

January 08, 2024

Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines The ALSAM Foundation, founded by the Skaggs family, provides lasting g...

04/01/2024

January 03, 2024

Life science entrepreneur Gene Lay joins Scripps Research Board of Directors Lay, founder of the global biotech company BioLegend, brings invaluable experience ...

21/12/2023

December 20, 2023

Taming a plant-derived toxin Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments. ...

19/12/2023

December 18, 2023

Scripps Research Executive Vice President Eric Topol gives TED talk on transformative power of AI in medicine Topol provides an overview of how AI models can i...

13/12/2023

December 12, 2023

New AI-powered algorithm could better assess people's risk of common heart condition Early detection of atrial fibrillation can reduce the risk of stroke an...

07/12/2023

December 06, 2023

Nanoparticle flu vaccine design shows promise in early tests Scripps Research-designed vaccine could provide broad, enduring protection against influenza A str...

16/11/2023

November 15, 2023

Numerous Scripps Research scientists named Highly Cited Researchers Clarivate's annual, global list represents researchers who have demonstrated significant...

07/11/2023

November 06, 2023

Multiple sclerosis drug invented at Scripps Research slows long-term devastating disease progression Late-breaking data reinforces the effectiveness and safety ...

05/10/2023

October 04, 2023

Keren Lasker named a 2023 Moore Inventor Fellow The prestigious award will support Lasker's inventive research in membraneless organelles and their applica...

22/09/2023

September 21, 2023

Michael Bollong named a 2023 Amgen Young Investigator The prestigious award will support Bollong's research identifying new molecular targets and therapeuti...

09/09/2023

September 08, 2023

Philip Dawson receives 2024 American Chemical Society National Award Dawson is honored with the Arthur C. Cope Late Careers Scholar Award for his foundational c...

07/09/2023

September 06, 2023

Scripps Research chemists devise a method for C-H activation of alcohols The method represents a new toolkit for making drugs and other compounds. September 06...

31/08/2023

August 30, 2023

Scripps Research receives $1.5M to surveil infectious disease threats in wastewater Bill & Melinda Gates Foundation award to support the development of multi-pa...

16/08/2023

August 16, 2023

How cold temperatures trigger the brain to boost appetite Scripps Research scientists' discovery could lead to new weight loss and metabolic health treatmen...

08/08/2023

August 07, 2023

Human antibody that targets carfentanil, fentanyl and related opioids reverses overdose effects in preclinical study Scripps Research-developed antibody therapy...

04/08/2023

August 03, 2023

How sensory neurons impact the gut Scripps Research scientists show that the receptor PIEZO2 in sensory neurons controls gut motility and transit time, which a...

26/07/2023

July 26, 2023

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets The expanded strategic collaboration will advan...

23/07/2023

July 21, 2023

Scripps Research scientists develop AI-based tracking and early-warning system for viral pandemics Machine-learning system effectively predicts emergence of pro...

19/07/2023

July 19, 2023

Monitoring T cells may allow prevention of type 1 diabetes Scripps Research study shows that analyzing T cells in blood samples could be used to select at-risk ...

19/07/2023

July 18, 2023

Scripps Research mourns passing of leading organic chemist Albert Eschenmoser Eschenmoser pioneered key reactions in synthetic chemistry and shaped the understa...

15/06/2023

June 14, 2023

Scripps Research awarded $46.8 million by NIH to promote human health through innovative translational science and training The Translational Institute is harne...

13/06/2023

June 13, 2023

Scripps Research's Danielle Grotjahn named 2023 Pew Scholar in the Biomedical Sciences The award will support Grotjahn's study of how cells assemble the...

31/05/2023

May 31, 2023

Crossing the ring: new method enables C-H activation across saturated carbocycles Scripps Research chemists add another powerful tool to their molecular editin...

24/05/2023

May 23, 2023

Scripps Research develops behind-the-scenes tool for better biomedical data discovery The new resource makes datasets more discoverable for life science communi...

19/05/2023

May 15, 2023

Scripps Research neuroscientist Hollis Cline elected to American Academy of Arts and Sciences Cline is recognized for her discoveries about the role of sensory ...

19/05/2023

May 18, 2023

Scripps Research's Skaggs Graduate School awards doctoral degrees to 31st graduating class Commencement ceremony will be livestreamed via Zoom and on instit...

13/05/2023

May 12, 2023

A better route to benzocyclobutenes, sought-after building blocks for drugs Scripps Research chemists devise a new, C-H activation-based method for the synthesi...

09/05/2023

May 08, 2023

Renowned Scripps Research professor Jeffery Kelly elected to National Academy of Sciences Kelly's groundbreaking work on protein misfolding has led to thera...

28/04/2023

April 27, 2023

Mirror-image molecules pave new path for cancer drug discovery By comparing how mirror image versions of small molecules impact clusters of proteins, Scripps R...

22/04/2023

April 21, 2023

How alcohol consumption contributes to chronic pain A Scripps Research team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and...

21/04/2023

April 20, 2023

Xin Jin receives dual awards to study autism risk genes in neurodevelopment Major grants from the National Institutes of Health and California Institute for Reg...

20/04/2023

April 19, 2023

Trim the sugar: New HIV vaccine design improves immune response Scripps Research vaccine candidate headed for clinical trials. April 19, 2023 LA JOLLA, CA A...

18/04/2023

April 17, 2023

Therapeutic can seek and destroy potent opioid to treat overdoses Scripps Research chemists developed a new biologic to work against the synthetic opioid carfen...

07/03/2023

March 06, 2023

How heavy alcohol consumption increases brain inflammation The findings by a Scripps Research team point toward a potential new drug target for treating alcohol...